晚期上皮性卵巢癌诊断时循环肿瘤DNA的预后价值及新辅助化疗一周期后早期下降的意义:CHIVA II期GINECO试验的辅助分析
该辅助分析纳入CHIVA试验中188例晚期上皮性卵巢癌患者,于诊断时(T0)及每周期新辅助化疗前采血行下一代测序检测循环肿瘤DNA。T0可检测到ctDNA者107例(63.7%),T1时137例(85.6%)ctDNA阴性或下降超过80%。ctDNA比值早期下降与无进展生存期(p=0.0017)和总生存期(p=0.0036)显著获益相关,并与更可能完成肿瘤细胞减灭术相关(OR 3.94,95%CI 1.45-10.70,p=0.0074)。
要点
- 晚期上皮性卵巢癌诊断时63.7%可检测到ctDNA。
- 新辅助化疗一周期后85.6%患者ctDNA阴性或下降超过80%。
- ctDNA早期下降与PFS、OS显著获益及更可能完成CRS相关。
核心结论
- ctDNA比值早期下降可在患者管理早期提供预后信息,有助于更准确地向患者告知病情并早期为肿瘤细胞减灭术做准备(预康复)。
研究设计与样本
- CHIVA II期GINECO试验(NCT01583322)的辅助分析,纳入188例晚期上皮性卵巢癌患者。
- 于诊断时(T0)及每周期新辅助化疗前采血,采用下一代测序检测循环肿瘤DNA。
- 采用多变量分析,p值0.05认为显著;用Cox生存模型寻找与PFS和OS相关的变量,Kaplan-Meier曲线图形展示PFS和OS差异,log-rank检验比较两条曲线。
主要发现
- 188例患者纳入分析;T0时有血样者168例,T0和T1均有血样以评估ctDNA比值动力学者160例。
- T0时可检测到ctDNA者107例(63.7%)。
- T1时ctDNA阴性或下降超过80%者137例(85.6%)。
- ctDNA比值早期下降者在PFS(p=0.0017)和OS(p=0.0036)方面均显著获益。
- 有利的ctDNA下降与更可能完成CRS相关(OR 3.94,95%CI 1.45-10.70,p=0.0074)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the prognostic impact of circulating tumor DNA (ctDNA) detection at diagnosis (T0) and its early decrease after one cycle (T1) of neoadjuvant chemotherapy (NACT) in patients with advanced epithelial ovarian cancer (EOC) included in the CHIVA trial (NCT01583322). METHODS: Blood samples were collected at T0 and before each administration of NACT. Circulating tumor DNA detection was performed by next-generation sequencing. Multivariate analysis was performed. A p-value of 0.05 was considered significant. Progression-free survival (PFS) and overall survival (OS) were compared between groups defined by ctDNA kinetic profile. Cox survival model was used to search variables associated with PFS and OS. Kaplan-Mayer curve was used to graphically express the differences in PFS and OS. A log-rank test compared the two curves. RESULTS: 188 patients were included. Blood samples were available for 168 patients at T0 and for 160 patients at T0 and T1 to assess ctDNA ratio kinetics. At T0, 107 patients (63.7 %) had detectable ctDNA. At T1, 137 (85.6 %) patients had negative ctDNA or a decrease of more than 80 %. There was a significant benefit in either PFS (p = 0.0017) or OS (p = 0.0036) in favor of early decrease of ctDNA ratio. A favorable decrease was associated with a greater likelihood of being able to perform CRS (OR: 3.94 (CI95 % 1.45-10.70), p = 0.0074). CONCLUSIONS: Early decrease of ctDNA ratio can provide prognostic information early in the management of patients, allowing a more accurate information to patients and an early preparation for CRS (prehabilitation).
引用
- Azaïs H, Brochard C, Taly V, et al. Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial. Gynecol Oncol. 2024. PMID: 39671779. doi:10.1016/j.ygyno.2024.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。